ASH 2019 | Emerging mutations at relapse in FLT3-mutated R/R AML on gilteritinib
Mark Levis
• 8 Dec 2019
The phase 3 ADMIRAL trial (NCT02421939) demonstrated that gilteritinib significantly prolonged OS compared with salvage chemotherapy in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), even in the presence of common co-occurring AML mutations. However, as with other FLT3 inhibitors, patients often develop resistance. Here, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the emerging mutations in patients who relapsed while receiving gilteritinib therapy in the ADMIRAL trial. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
